If there is a trial ongoing at DF and a trial ongo

If there is a trial ongoing at DF and a trial ongoing at BI overseas strictly regarding KEVETRIN, then shouldn't we have twice the data for our empirical results after each cohort?  Since DF and BI are related, wouldn't they share all data and that data should pretty much mirror one another?  Taking this a step further, we should thus reach a level of assuredness regarding the data findings much quicker than if we only had one trial ongoing.  Also makes me wonder if they are trying to keep each trial on the same schedule as to starting new cohorts or if they are purposely staggering the trials for some reason or another.  Also makes me wonder what happens if one trial finds a considerably different MTD than the other  or shows statistically significant differences in results?

Will wait for seel to respond as to how, if at all, these two trials at sister facilities will help one another and share data.